Finoptinum

Pharmacological action

Active agent – verapamil a hydrochloride. Drug is derivative a difenilalkilamina, belongs to the selection locks of calcium channels of the I class. Has anti-hypertensive, antiarrhytmic and anti-anginal effect.

The anti-anginal effect is caused as well as direct impact on a myocardium, and action on peripheral geodynamics. Blocking intake of calcium in a cell, Finoptinum puts to decrease in transformation of the energy concluded in it in mechanical action, thus, reducing contractility of a myocardium.

Finoptinum considerably reduces atrioventricular conductivity and increases the refrakternost period. At supraventricular arrhythmias has antiarrhytmic effect.

Pharmacokinetics

At oral administration Finoptinum, getting in an organism, it is absorbed for 90%. Metabolism happens in a liver at "the first passing". The main metabolite – norverapamit. The elimination half-life, at one-time reception, makes – 2,5-7,5 hours, at further receptions of 4,5-12 hours. Drug is removed generally by kidneys and from 9 to 16% through intestines. After intravenous administration the elimination half-life is equal to 2-5 hours.

Indications to use of Finoptinum

• stenocardia (stable without vasomotor spasm, vasospastic);
• sinus tachycardia;
• supraventricular tachycardia;
• hypertensive crisis;
• ciliary tachyarrhythmia;
• primary hypertensia;
• atrial premature ventricular contraction;
• atrial flutter;
• arterial hypertension;
• hypertrophic subaortic stenosis.

Dosage of Finoptinum and instruction for reception

Internal reception – an initial dose 40-80 mg, 3 times a day. For the prolonged Finoptinum forms the single dose has to be increased, and the frequency of reception is reduced.

Perhaps intravenous administration of Finoptinum (struyno) – slowly, controlling the arterial pressure and the patient's pulse. To patients with the expressed liver dysfunction the daily dose of Finoptinum should not exceed 120 mg. The most admissible dose for adult patients at intake – 480 mg a day.

Side effects of Finoptinum

From cardiovascular system: obviously expressed lowering of arterial pressure, tachycardia, bradycardia, aggravation of heart failure; seldom - a myocardial infarction, stenocardia, arrhythmia; at bystry intravenous administration – a collapse, an atrioventricular block of the III degree, an asystolia.

From the central nervous system and peripheral nervous system: a depression, increased fatigue, dizziness, an adynamy, uneasiness, a syncope, block, drowsiness, a headache, extrapyramidal disturbances (trembling of hands, a mask-like face, the ataxy shuffling gait, swallowing difficulty, rigidity of extremities).

From the alimentary system: increase in appetite, a lock (it is rare - diarrhea), nausea, a hyperplasia of gums.

Other possible side effects of Finoptinum: increase in body weight, is extremely rare - a gynecomastia, an agranulocytosis, a galactorrhoea, a giperprolaktinemiya, arthritis, a fluid lungs, peripheral hypostases, thrombocytopenia asymptomatic.

Contraindications to use

• pregnancy;
• sinuatrial blockade;
• lactation period;
• atrioventricular block of II and III degrees;
• heavy arterial hypotension;
• hypersensitivity to Finoptinum.

Reception of Finoptinum at pregnancy and a lactation

In the period of a lactation and at pregnancy Finoptinum is contraindicated to use.

Special instructions

According to the instruction Finoptinum should be applied with care:

• at a myocardial infarction with a left ventricular failure;
• at heart failure in a chronic form;
• at bradycardia;
• at Avblokade - the I degree;
• at a liver failure;
• at a heavy stenosis of the mouth of an aorta;
• at a renal failure;
• at slight or moderate arterial hypotension;
• to patients of advanced age;
• to children and teenagers 18 years are younger.

Influence on ability to work of the demanding concentration

After reception of Finoptinum manifestations of drowsiness and dizziness are possible that can negatively affect concentration of attention.

Medicinal interaction of Finoptinum

Combination Finoptinas anti-hypertensive drugs such kak:vazodilatator, APF inhibitors, thiazide diuretics, leads to mutual strengthening of anti-hypertensive effect.

Simultaneous use with beta adrenoblockers, means for an inhalation anesthesia, antiarrhytmic drugs, increases risk of development of bradycardia, heart failure, arterial hypotension. At parenteral administration of Finoptinum to the patients receiving beta adrenoblockers there is a risk of development of an asystolia and arterial hypotension.

At a combination Finoptinas cases of increase in a bleeding time are known for acetylsalicylic acid. The concomitant use with digoxin leads to increase in concentration of digoxin in a blood plasma.

The combination to Disopyramidum can cause heavy arterial hypotension and a collapse. Simultaneous use with diclofenac reduces concentration of verapamil in a blood plasma.

At reception, patients with arterial hypertension, Finoptinum with a clonidine, recorded cardiac standstill cases.

The concomitant use with phenobarbital or Phenytoinum can cause decrease in concentration of verapamil in blood.

Finoptinum combination with enflurany or etomidaty can cause increase in time of effect of anesthesia.